Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
Contact: Marketed Health Products Directorate (MHPD)
The Health Products and Food Branch (HPFB) posts on the Health Canada Web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.
This is duplicated text of a letter from Dana Douglas Inc.
Contact the company for a copy of any references, attachments or enclosures.
Public Communication
Health Canada Endorsed Important Safety Information on neXus I, II and III Rollators
February 2, 2010
Subject: Recall of neXus I, II and III Rollators due to potential health and safety risk
Dana Douglas Inc. has initiated a voluntary recall of certain neXus I, II and III rollators. Affected rollators may break during use, which could result in the user falling and suffering serious injury including bruising, broken bones or death. Rollators with the serial numbers indicated in bold below are affected by this recall (serial numbers are located on the inside rear leg of rollators).
neXus 1 Model #4520 with serial numbers
neXus 2 Model #4515 with serial numbers
neXus 3 Model #4500 with serial numbers
neXus 3 Model #4500T with tall handles and serial numbers between 91164-40 and 102792-40
Individuals are advised to stop using affected rollators immediately and to return their rollator to an authorized dealer for necessary modifications. For any questions about the recall, or to locate an authorized dealer, contact Dana Douglas by email at info@danadouglas.com or by telephone, fax or postal mail at the contact information below.
Dana Douglas has identified four potential issues with the rollators. Each issue and the serial numbers affected by the issue are discussed separately below.
Rollators with the Super Low, Low and Standard seat heights bearing one of the serial numbers indicated immediately below may experience a weakening below the weld on the rear frame which could result in breakage when used by consumers weighing more than 85 kilos (187 pounds).
There have been 75 reported incidents of the rear frame breaking on the neXus 1 and 2 models of which six (6) have resulted in falls and bruising to the user. There have been 145 reported incidents of the rear frame breaking on the neXus 3 model. No injuries have resulted from the incidents involving the neXus 3 model.Installation of manufacturer-supplied reinforcement brackets at the rear frame weld will increase the product's weight capacity to the advertised maximum user weight of 113 kilos (250 pounds.)
Note: Rollators distributed since October 30, 2009 are rated for use by customers up to 113 kilos (max. 250 pounds.)Managing marketed health product-related adverse incidents depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported postmarket adverse incidents are generally presumed to underestimate the risks associated with health product use. Any cases of falls resulting in bruising, broken bones or death or other serious or unexpected adverse incidents in persons using neXus rollators should be reported to Dana Douglas Inc. or Health Canada at the following addresses:
Any suspected adverse reaction can also be reported to:
Health Products and Food Branch Inspectorate
Health Canada
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Telephone: The Inspectorate Hotline 1-800-267-9675
The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada Web site.
For other inquiries related to this communication, please contact Health Canada at: